Skip to navigation Skip to content

Clinical Trial: Ocrelizumab vs. fingolimod in children and adolescents with MS

Share

Details
Type of MS: RRMS
Treatment mode of action: To affect immune function
Number of Subjects: 233
Medication: Ocrelizumab vs. fingolimod
Location: Colorado|Massachusetts|Ohio
Institutions: Multicenter, US and Canada Contact Information
Roche, refer to study ID WN42086
888-662-6728
global-roche-genentech-trials@gene.com

Funding:

Roche

Description

Study is seeking to assess the safety and effectiveness of ocrelizumab (administered by intravenous infusion every 24 weeks) in comparison to fingolimod (one oral capsule taken once per day) in children and adolescents ages 10 to 18 with relapsing-remitting MS. The study is controlled, meaning that participants who are taking ocrelizumab will take an oral placebo, and participants taking fingolimod will take a sham infusion. The study requires 14 visits; mobile nursing visits at home are available for four of these visits. The study involves site visits, MRI scans, urine analysis and blood draws. 

Share


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.